TX-FLUENCE
9.5.2022 14:02:07 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its sponsorship of Wageningen University & Research’s (WUR) third Autonomous Greenhouse Challenge in the Netherlands. For the first time in the challenge’s history, WUR leveraged a broad-spectrum LED-only lighting system—specifically Fluence’s VYPR 3p solution—instead of high-pressure sodium (HPS) fixtures. WUR also implemented Fluence’s innovative lighting control solution, Wireless Flex Dimming, into the facility.
Wageningen University & Research is dedicated to researching the future of agriculture by exploring autonomous greenhouse technology, climate control, crop modeling, advanced sensors, data intelligence, computer vision and robotics. Beginning in June 2021, WUR organized its third Autonomous Greenhouse Challenge to task different international teams with sustainably growing vegetables in a fully automated greenhouse environment.
“We expect that food production in greenhouse horticulture can be further improved by adding more artificial intelligence to the agricultural industry,” said Silke Hemming, who leads the scientific research team for greenhouse technology at WUR, in a statement . “We make connections with international partners through this unique challenge, so that we can take major steps.”
One of the challenges growers face when transitioning from HPS to LED luminaires is that a typical HPS system is limited in its dimming capabilities, unlike LED technology. By leveraging state-of-the-art, qualified Bluetooth mesh technology enabled by Technology Partner SILVAIR, Fluence’s Wireless Flex Dimming solution allows growers to have precise control of dim light levels. By connecting the VYPR top light fixtures to the climate computer through Wireless Flex Dimming, the participants were empowered to implement advanced lighting control strategies that maximized plant growth and quality.
“In any greenhouse or controlled environment, the reliability of a cultivation system is paramount,” said Theo Tekstra, Fluence’s technical director for Europe, Middle East and Africa. “Wireless Flex Dimming enables growers to simplify installation and gain solid wireless control of their light levels, whether in an autonomous scientific experiment or a large-scale greenhouse. We are now implementing this technology for customers with more than 7,000 connected fixtures.”
WUR’s Autonomous Greenhouse Challenge also seeks to discover how artificial intelligence can play a role in the future of cultivation, including how to reduce energy input and cost.
“The complete cultivation process is handled by AI and algorithms developed by the teams,” Tekstra added. “One important input factor is the strong fluctuations in high energy prices. Fluence’s Wireless Flex Dimming integration with the Ridder climate computer allows the teams to modulate the lights within their lighting strategy algorithms to optimize energy costs. Fluence’s mission is to help the world grow smarter—something these incredible teams are tackling head-on. We are delighted to support WUR and this initiative with our advanced lighting solutions.”
Fluence continues to demonstrate how secure, intelligent lighting solutions based on the latest technology innovations can add value to the global horticulture industry. The Wireless Flex Dimming Receiver has been awarded PSA Certified™ Level 1 (an independent measurement of security best practices spearheaded by Arm) from Riscure. PSA Certified is recognized by the DesignLights Consortium as an approved cybersecurity standard for networked lighting control systems.
Results from the challenge will be published in July 2022. To follow the competing teams’ progress, visit WUR’s greenhouse challenge dashboard here . For more information on Fluence and its portfolio of controls and luminaires, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom